NEW YORK: Pfizer reported a jump in second-quarter profits on Thursday behind a near doubling of revenues driven by sales of its COVID-19 vaccine and therapeutic drug Paxlovid.
US officials last month approved emergency authorisation to Pfizer and Moderna for COVID-19 vaccines in under-five-year-olds, the final age group awaiting immunisation in most countries.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: